REFERENCES
- Barnes P J. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269–280, [INFOTRIEVE], [CSA]
- Celli B R, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946, [INFOTRIEVE], [CSA]
- Anthonisen N R, Connett J E, Murray R P. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675–679, [INFOTRIEVE], [CROSSREF], [CSA]
- Donaldson G C, Seemungal T A, Bhowmik A, Wedzicha J A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57: 847–852, [INFOTRIEVE], [CROSSREF], [CSA]
- Sutherland E R, Cherniack R M. Management of chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2689–2697, [INFOTRIEVE], [CROSSREF], [CSA]
- Sutherland E R, Allmers H, Ayas N T, Venn A J, Martin R J. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: A meta-analysis. Thorax 2003; 58: 937–941, [INFOTRIEVE], [CROSSREF], [CSA]
- Pryor W A, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci 1993; 686: 12–27, [INFOTRIEVE], [CSA]
- Pratico D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald G A. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Crit Care Med 1998; 158: 1709–1714, [INFOTRIEVE], [CSA]
- Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996; 154: 1055–1060, [INFOTRIEVE], [CSA]
- Tager M, Piecyk A, Kohnlein T, Thiel U, Ansorge S, Welte T. Evidence of a defective thiol status of alveolar macrophages from COPD patients and smokers. Chronic obstructive pulmonary disease. Free Radic Biol Med 2000; 29: 1160–1165, [INFOTRIEVE], [CROSSREF], [CSA]
- Crapo J D. Oxidative stress as an initiator of cytokine release and cell damage. Eur Respir J Suppl 2003; 44: 4s–6s, [INFOTRIEVE], [CROSSREF], [CSA]
- Decramer M, Rutten-van Molken M, Dekhuijzen P N, Troosters T, van Herwaarden C, Pellegrino R, van Schayck C P, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552–1560, [INFOTRIEVE], [CROSSREF], [CSA]
- Moher D, Cook D J, Eastwood S, Olkin I, Rennie D, Stroup D F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of Meta-analyses. Lancet 1999; 354: 1896–1900, [INFOTRIEVE], [CROSSREF], [CSA]
- Sterne J AC, Bradburn M J, Egger M. Meta-analysis in Stata. Systematic reviews in health care: meta-analysis in context, M Egger, D G Altman, G D Smith. BMJ Books, London 2001
- Cochran W G. the combination of estimates from different experiments. Biometrics 1954; 10: 101–129, [CROSSREF], [CSA]
- Light R J, Singer J D, Willett J B. The visual presentation and interpretation of meta-analysis. The handbook of research synthesis, H Cooper, L V Hedges. Russell Sage Foundation, New York 1994; 439–454
- Begg C B, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101, [INFOTRIEVE], [CROSSREF], [CSA]
- Light R J, Pillemar D B. Summing up: the science of reviewing research. Harvard University Press, Cambridge, MA 1984
- Sackett D L, Haynes R B, Guyatt G H, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. Little, Brown and Company, Boston 1991
- Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983; 64: 405–415, [INFOTRIEVE], [CSA]
- British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax 1985; 40: 832–835, [CSA]
- Grassi C, Morandini G C. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol 1976; 09: 393–396, [INFOTRIEVE], [CROSSREF], [CSA]
- Hansen N C, Skriver A, Brorsen-Riis L, Balslov S, Evald T, Maltbaek N, Gunnersen G, Garsdal P, Sander P, Pedersen J Z, Ibsen T B, Rasmussen F V. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994; 88: 531–535, [INFOTRIEVE], [CROSSREF], [CSA]
- Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis. a double-blind controlled study. Eur J Respir Dis 1980; 61: 93–108, Suppl. 111[CSA]
- Pela R, Calcagni A M, Subiaco S, Isidori P, Tubaldi A, Sanguinetti C M. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 1999; 66: 495–500, [INFOTRIEVE], [CROSSREF], [CSA]
- Rasmussen J B, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1988; 1: 351–355, [INFOTRIEVE], [CSA]
- Halliwell B, Gutteridge J MC. Free radicals in biology and medicine. 3rd ed. Oxford University Press, OxfordEngland 1999
- van d er, Vliet A, O'Neill C A, Cross C E, Koostra J M, Volz W G, Halliwell B, Louie S. Determination of low-molecular-mass antioxidant concentrations in human respiratory tract lining fluids. Am J Physiol 1999; 276: L289–296, [CSA]
- Kinnula V L, Crapo J D. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 2003; 167: 1600–1619, [INFOTRIEVE], [CROSSREF], [CSA]
- Linden M, Hakansson L, Ohlsson K, Sjodin K, Tegner H, Tunek A, Venge P. Glutathione in bronchoalveolar lavage fluid from smokers is related to humoral markers of inflammatory cell activity. Inflammation 1989; 13: 651–658, [INFOTRIEVE], [CROSSREF], [CSA]
- Muller T, Gebel S. The cellular stress response induced by aqueous extracts of cigarette smoke is critically dependent on the intracellular glutathione concentration. Carcinogenesis 1998; 19: 797–801, [INFOTRIEVE], [CROSSREF], [CSA]
- Verstraeten J M. Mucolytic treatment in chronic obstructive pulmonary disease. Double-blind comparative clinical trial with N-acetylcysteine, bromhexine and placebo. Acta Tuberc Pneumol Belg 1979; 70: 71–80, [INFOTRIEVE], [CSA]
- Grandjean E M, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000; 22: 209–221, [INFOTRIEVE], [CROSSREF], [CSA]
- Poole P J, Black P N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003, CD001287[CSA]
- Stey C, Steurer J, Bachmann S, Medici T C, Tramer M R. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16: 253–262, [INFOTRIEVE], [CROSSREF], [CSA]
- Burge P S, Calverley P M, Jones P W, Spencer S, Anderson J A, Maslen T K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–1303, [INFOTRIEVE], [CROSSREF], [CSA]
- Donohue J F. Still looking for answers in COPD. Lancet 2005; 365: 1518–1520, [INFOTRIEVE], [CROSSREF], [CSA]
- Alsaeedi A, Sin D D, McAlister F A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59–65, [INFOTRIEVE], [CROSSREF], [CSA]